Is FBRX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The argenx acquisition, with deal price (cash per share) at $77.00. The bear case rests on for former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment. Analysts covering it are spread from $61.00 to $77.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. For former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $61.00, -20.8% from the $76.99 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The argenx acquisition. argenx agreed on July 26, 2026 to buy Forte for $77.00 per share in cash, ran a tender offer from August 6 to August 26, and closed the merger on August 27, 2026. The most optimistic analyst target on FBRX is $77.00, +0.0% from the $76.99 price. That figure is only reachable if this thesis works close to its best case.

For former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment. The remaining practical matters are administrative: holders who did not tender should confirm with their broker or Computershare that payment was received, and any holder who sought appraisal under Section 262 of Delaware law faces the uncertainty and cost of that court process instead of the deal price. Cash received may create a taxable gain or loss. Anyone who wants continued exposure to FB102 would now have to consider argenx, a much larger and more diversified company with its own separate risks. Walnut is not an investment adviser, so this is descriptive context, not a recommendation. The most pessimistic published target is $61.00, -20.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Forte Biosciences (NASDAQ: FBRX) is a Dallas-based clinical-stage biopharmaceutical company built around a single lead candidate, FB102, a proprietary anti-CD122 monoclonal antibod

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The argenx acquisition) stalling in the reported numbers rather than in the narrative, the risk above (for former FBRX shareholders, the operating risks that once defined the stock (single-asset trial failure, cash burn, dilution, and competition) no longer apply to them, because the merger converted their shares into a fixed $77.00 cash payment) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody, as a potential treatment for autoimmune conditions including celiac disease, vitiligo, and alopecia areata. Since August 27, 2026 it has been a wholly owned subsidiary of argenx, and its stock no longer trades.

No. Forte was pre-commercial and reported zero product revenue. Its net loss was about $22 million in Q1 2026 and about $88 million over the twelve months to June 2026, funded from equity raises. Its financials are now part of argenx.

FB102 is Forte's lead and only clinical candidate, a proprietary anti-CD122 antibody. CD122 is part of the IL-15 signaling pathway linked to autoimmune-driving T cells, which is why Forte tested FB102 across several autoimmune indications from a single molecule. argenx now owns the program.